PharmEasy IPO refers to the proposed initial public offering of API Holdings Limited, the parent company of PharmEasy. API Holdings had filed its Draft Red Herring Prospectus (DRHP) with SEBI in November 2021 for a proposed Mainboard Book Built IPO of up to ₹6,250 crore. The earlier proposal consisted of a fresh issue of equity shares, with no Offer for Sale proposed in the DRHP. The company does not have an identifiable promoter.
The earlier IPO proposal included a fresh issue of up to ₹6,250 crore. The company had proposed using the proceeds for repayment or prepayment of borrowings, funding organic growth initiatives, pursuing inorganic growth through acquisitions and strategic initiatives, and general corporate purposes. The earlier DRHP also stated that the company could consider a pre-IPO placement of up to ₹1,250 crore, in which case the fresh issue size would be reduced accordingly.
API Holdings operates an integrated healthcare platform that includes PharmEasy’s digital healthcare marketplace along with pharmaceutical distribution, diagnostics, technology and other healthcare businesses. The group has businesses including PharmEasy, Retailio, Thyrocare and Aknamed-related healthcare operations. The company’s latest FY2025-26 annual report states that it earns revenue through the sale of products and services, including pharmaceutical distribution, hospital supplies, diagnostics and services delivered through its technology platforms.
As of September 2026, there is no confirmed IPO opening date, price band, lot size, subscription schedule or listing date for a new PharmEasy IPO. The earlier 2021 IPO documents should therefore be treated as historical proposed-issue information rather than as a current IPO timetable. Current company information and financial performance are available through API Holdings’ FY2025-26 annual report.
Table of Contents
PharmEasy IPO Details Information
The key IPO information from the earlier API Holdings DRHP is given below. Current IPO dates, price band, lot size and final issue structure are yet to be officially announced for a new PharmEasy IPO.
| Particulars | Information |
|---|---|
| IPO Name | PharmEasy IPO |
| Company Name | API Holdings Limited |
| IPO Type | Book Build Issue |
| IPO Category | Mainboard IPO |
| Face Value | ₹1 Per Equity Share |
| Price Band | Yet to be Updated |
| Issue Size | Up to ₹6,250 Crore under the 2021 DRHP |
| Fresh Issue | Up to ₹6,250 Crore under the 2021 DRHP |
| Offer for Sale | Nil under the 2021 DRHP |
| IPO Open Date | Yet to be Updated |
| IPO Close Date | Yet to be Updated |
| Anchor Investor Bidding | Yet to be Updated |
| Basis of Allotment | Yet to be Updated |
| Refund Initiation | Yet to be Updated |
| Shares Credited to Demat Account | Yet to be Updated |
| Listing Date | Yet to be Updated |
| Listing Exchange | BSE & NSE |
| Lot Size | Yet to be Updated |
| Registrar | Link Intime India Private Limited |
| Book Running Lead Managers | Kotak Mahindra Capital Company Limited, Morgan Stanley India Company Private Limited, BofA Securities India Limited, Citigroup Global Markets India Private Limited and JM Financial Limited |
The earlier DRHP proposed a fresh issue of up to ₹6,250 crore and stated that the equity shares were proposed to be listed on BSE and NSE. The DRHP named Kotak Mahindra Capital Company, Morgan Stanley India Company, BofA Securities India, Citigroup Global Markets India and JM Financial as the Book Running Lead Managers, with Link Intime India as the registrar.
PharmEasy IPO Dates
The current PharmEasy IPO opening, closing, allotment and listing dates have not been officially announced. The dates contained in the earlier IPO documents were part of a proposed 2021-22 issue and should not be presented as current 2026 IPO dates.
| IPO Event | Date |
|---|---|
| Anchor Investor Bidding | Yet to be Updated |
| IPO Opening Date | Yet to be Updated |
| IPO Closing Date | Yet to be Updated |
| Basis of Allotment | Yet to be Updated |
| Refund Initiation | Yet to be Updated |
| Shares Credited to Demat Account | Yet to be Updated |
| Listing Date | Yet to be Updated |
PharmEasy IPO Reservation
The reservation structure in the earlier proposed IPO followed the standard Mainboard IPO allocation framework stated in the available issue information.
| Investor Category | Reservation |
|---|---|
| Qualified Institutional Buyers (QIB) | Not Less Than 75% |
| Non-Institutional Investors (NII) | Not More Than 15% |
| Retail Individual Investors (RII) | Not More Than 10% |
The final reservation for any future PharmEasy IPO will depend on the fresh offer documents and the applicable SEBI regulations at the time of the issue.
PharmEasy IPO Lot Size
The current PharmEasy IPO lot size and application amount have not been announced. The price band and lot size will need to be disclosed in the final offer documents before investors can calculate the minimum application amount.
| Application | Shares | Amount |
|---|---|---|
| Retail Minimum | Yet to be Updated | Yet to be Updated |
| Retail Maximum | Yet to be Updated | Yet to be Updated |
| S-HNI Minimum | Yet to be Updated | Yet to be Updated |
About API Holdings Limited
API Holdings Limited is the parent company of the PharmEasy healthcare platform. The company operates an integrated healthcare business using technology and fulfilment capabilities across pharmaceutical products, healthcare services, diagnostics and distribution.
The company was incorporated as API Holdings Private Limited on March 31, 2019 and was subsequently converted into a public limited company in October 2021. The company’s FY2025-26 annual report identifies its registered and corporate office at Turbhe, Navi Mumbai, Maharashtra.
API Holdings’ business has expanded beyond the consumer-facing PharmEasy platform. Its operations include pharmaceutical distribution to retailers and chemists, hospital supply through Aknamed, diagnostics through Thyrocare, technology-enabled healthcare services and other healthcare-related activities.
The company’s FY2025-26 annual report states that it generated ₹66,185 million of consolidated revenue from operations during Fiscal 2026, compared with ₹58,722 million in Fiscal 2025. The company also reported improvement in EBITDA before exceptional items and ESOP expense, which moved to positive 1.5% of revenue in Fiscal 2026 from negative 3.0% in Fiscal 2025.
Business Operations
API Holdings operates across several healthcare and pharmaceutical business areas.
- PharmEasy – The digital healthcare marketplace provides access to medicines, healthcare products, diagnostics and related healthcare services.
- Pharmaceutical Distribution – The group distributes pharmaceutical, OTC, surgical, consumable and private-label products through technology-enabled channels.
- Retailio – Retailio provides technology and distribution capabilities connecting pharmaceutical wholesalers, pharmacies and other healthcare participants.
- Hospital Supply – Aknamed operates in the hospital supply business and serves healthcare institutions.
- Diagnostics – Thyrocare provides diagnostic testing services through its laboratory and franchise network.
- Healthcare Services – The group also provides technology, fulfilment, teleconsultation and other healthcare-related services.
During Fiscal 2026, API Holdings reported ₹56,700 million of revenue from sale of products and ₹9,413 million from sale of services. Retailio 1P generated ₹38,579 million, while Aknamed’s hospital supply business generated ₹8,470 million during the year.
Industry Overview
The Indian digital healthcare and pharmaceutical distribution market has developed with increasing adoption of online healthcare platforms, digital ordering, technology-enabled pharmacy distribution, diagnostics and integrated healthcare services.
The business environment combines consumer healthcare demand with pharmaceutical distribution, diagnostics and technology-enabled healthcare delivery. API Holdings operates across several of these segments rather than relying only on online medicine ordering.
The company’s latest annual report indicates a focus on higher-margin customer segments, improved customer experience, increased wallet share, greater capacity utilisation and integration of its supply chain. The group also expanded its diagnostic testing capabilities and reported growth in its franchisee network during Fiscal 2026.
Business Strategy
API Holdings’ current strategy focuses on improving operating efficiency, increasing revenue from profitable customer segments and strengthening margins across its businesses.
The company has focused on increasing wallet share from existing customers, targeting higher lifetime-value therapies, optimising marketing expenditure and improving fulfilment capabilities. It has also worked on supply-chain rationalisation, warehouse utilisation and cost optimisation.
The FY2025-26 annual report also highlights the company’s focus on higher-margin products, private-label products, diagnostics, generic pharmaceutical products and comprehensive healthcare opportunities. The company has also entered the quick-commerce segment through its digital capabilities.
PharmEasy IPO Financial Information
A company’s financial performance provides insights into revenue growth, profitability, operational efficiency and financial position. The latest audited consolidated financial information available from API Holdings’ FY2025-26 annual report provides the most recent financial picture of the company.
API Holdings Financial Summary
| Particulars | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Revenue from Operations | ₹5,664.29 Crore | ₹5,872.16 Crore | ₹6,618.50 Crore |
| Total Income | ₹5,758.94 Crore | ₹5,980.03 Crore | ₹6,689.29 Crore |
| EBITDA | -₹1,578.98 Crore | -₹841.80 Crore | ₹110.12 Crore |
| Profit Before Tax (PBT) | -₹2,522.85 Crore | -₹1,516.89 Crore | -₹456.10 Crore |
| Profit After Tax (PAT) | -₹2,534.39 Crore | -₹1,572.39 Crore | -₹520.29 Crore |
| Net Worth | ₹2,588.31 Crore | ₹3,272.28 Crore | ₹3,427.21 Crore |
| Total Borrowings | ₹4,098.00 Crore | ₹2,033.67 Crore | ₹1,332.29 Crore |
| Total Assets | ₹8,389.66 Crore | ₹6,976.58 Crore | ₹6,481.07 Crore |
The latest audited consolidated financial statements show revenue from operations of ₹6,618.50 crore in FY2026 compared with ₹5,872.16 crore in FY2025. The company’s loss after tax narrowed to ₹520.29 crore in FY2026 from ₹1,572.39 crore in FY2025. Consolidated borrowings declined to approximately ₹1,332.29 crore at March 31, 2026 from approximately ₹2,033.67 crore at March 31, 2025.
The company’s FY2025-26 annual report also states that EBITDA before exceptional items and ESOP expense improved to positive 1.5% of revenue in Fiscal 2026 compared with negative 3.0% in Fiscal 2025.
PharmEasy IPO Key Performance Indicators (KPIs)
Key Performance Indicators help investors assess the company’s operating and financial performance. The latest annual report provides several financial measures, including EBITDA margin before exceptional items and ESOP expense, loss margins, cash flow and EPS.
| KPI | Value |
|---|---|
| EBITDA Margin before Exceptional Items and ESOP | 1.5% |
| Loss before Exceptional Items and Tax Margin | -6.9% |
| PAT Margin | -7.9% |
| Debt-to-Equity Ratio | 0.39x |
| EPS | -₹0.37 |
| Net Asset Value (NAV) Per Share | Yet to be Updated |
The FY2026 consolidated financial statements report basic and diluted EPS of -₹0.37 per equity share of face value ₹1. The company reported an improvement in operating profitability, while the consolidated loss after tax remained ₹520.29 crore.
The company’s FY2026 operating cash flow was positive at ₹77.2 crore, compared with negative ₹210.9 crore in FY2025. The annual report also states that core working-capital days improved from 50 days in March 2025 to 42 days in March 2026.
Objects of the PharmEasy IPO
Under the earlier 2021 proposed IPO, API Holdings intended to utilise the fresh issue proceeds for the following purposes:
- Repayment or pre-payment of certain outstanding borrowings.
- Funding organic growth initiatives.
- Pursuing inorganic growth through acquisitions and strategic initiatives.
- General corporate purposes.
The earlier proposed fresh issue was up to ₹6,250 crore. The company had also disclosed that a pre-IPO placement of up to ₹1,250 crore could be considered, which would reduce the fresh issue size by the amount raised through such placement.
Any future PharmEasy IPO would require a fresh offer document specifying the updated objects of the issue.
PharmEasy IPO Listing Performance
API Holdings is not currently listed on the BSE or NSE. Therefore, there is no current PharmEasy IPO listing price or listing gain to report.
| Particular | Value |
|---|---|
| Listing Exchange | BSE & NSE |
| Listing Date | Yet to be Updated |
| Issue Price | Yet to be Updated |
| Listing Price | Yet to be Updated |
| Listing Gain | Yet to be Updated |
| Listing Gain (%) | Yet to be Updated |
The earlier DRHP proposed listing the equity shares on BSE and NSE, but the current listing date and final issue price have not been announced.
PharmEasy IPO Subscription Status
There is currently no live PharmEasy IPO subscription period. Therefore, current QIB, NII, retail and total subscription figures are not available.
PharmEasy IPO Subscription
| Investor Category | Subscription |
|---|---|
| Qualified Institutional Buyers (QIB) | Yet to be Updated |
| Non-Institutional Investors (NII) | Yet to be Updated |
| Retail Individual Investors (RII) | Yet to be Updated |
| Employee Category | Yet to be Updated |
| Total Subscription | Yet to be Updated |
Subscription figures will be available only after a future IPO is officially opened for bidding.
PharmEasy IPO Review
API Holdings operates a broad healthcare platform through PharmEasy and other businesses covering pharmaceutical distribution, diagnostics, hospital supplies and technology-enabled healthcare services.
The company’s latest FY2026 financial results show revenue from operations of ₹6,618.50 crore, up from ₹5,872.16 crore in FY2025. The company also reported a substantial reduction in consolidated loss, with loss after tax declining from ₹1,572.39 crore in FY2025 to ₹520.29 crore in FY2026.
The company also reported positive EBITDA before exceptional items and ESOP expense as a percentage of revenue in FY2026, at 1.5%, compared with negative 3.0% in FY2025. At the same time, the company continued to report a consolidated net loss and had outstanding borrowings at March 31, 2026.
For a future PharmEasy IPO, investors would need to consider the company’s revenue growth, improvement in operating profitability, remaining losses, debt position, healthcare business mix, competitive environment, regulatory requirements and the final valuation and offer structure.
PharmEasy IPO Strengths
- Integrated healthcare platform covering multiple healthcare and pharmaceutical businesses.
- PharmEasy provides a recognised digital healthcare marketplace.
- Presence across pharmaceutical distribution, diagnostics and hospital supply.
- Revenue from operations increased from ₹5,872.16 crore in FY2025 to ₹6,618.50 crore in FY2026.
- EBITDA before exceptional items and ESOP expense improved to positive 1.5% of revenue in FY2026.
- Consolidated borrowings declined from approximately ₹2,033.67 crore in FY2025 to approximately ₹1,332.29 crore in FY2026.
- Diagnostic capabilities through Thyrocare and technology-enabled healthcare services provide additional business segments.
PharmEasy IPO Risk Factors
- The company continued to report a consolidated net loss in FY2026.
- The healthcare and pharmaceutical distribution markets are highly competitive.
- The business is subject to healthcare, pharmaceutical, diagnostic and data-related regulatory requirements.
- The company operates across several businesses, creating operational and integration requirements.
- Changes in customer acquisition costs and consumer behaviour may affect the digital healthcare business.
- Pharmaceutical distribution businesses require working capital and efficient inventory and receivables management.
- Future IPO valuation and issue structure may materially affect the investment characteristics of the offer.
PharmEasy IPO Promoters
API Holdings does not have an identifiable promoter. The earlier DRHP expressly stated that the company does not have an identifiable promoter.
PharmEasy IPO Promoters Details :
| Promoter | Designation |
|---|---|
| No Identifiable Promoter | Not Applicable |
The company’s ownership includes institutional and other shareholders rather than a single identifiable promoter.
PharmEasy IPO Management Team
The latest API Holdings annual report identifies Rahul Guha as Managing Director and Chief Executive Officer, Siddharth Shah as Executive Director and Vice Chairman, Alok Kumar Jagnani as Whole Time Director and Group Chief Financial Officer, and Drashti S. Shah as Group General Counsel and Company Secretary.
| Name | Designation |
|---|---|
| Rahul Guha | Managing Director and Chief Executive Officer |
| Siddharth Shah | Executive Director and Vice Chairman |
| Alok Kumar Jagnani | Whole Time Director and Group Chief Financial Officer |
| Drashti S. Shah | Group General Counsel and Company Secretary |
| Aditya Puri | Chairman and Non-Executive Director |
| Bobby Parikh | Independent Director |
| Archana Bhaskar | Independent Director |
| Deepak Vaidya | Independent Director |
| Mayank Bajpai | Non-Executive Director |
| Dr. Ranjan Pai | Non-Executive Director |
| Shyam Powar | Non-Executive Director |
| Ravi Rajagopal | Non-Executive Director |
| Ashutosh Sharma | Non-Executive Director |
| Subramaniam Somasundaram | Independent Director |
| Vineeta Rai | Independent Director |
| Dr. Jaydeep Tank | Independent Director |
| Ankur Thadani | Non-Executive Director |
The FY2025-26 annual report records the appointments and board composition as applicable during and after the financial year, including changes effective in August and September 2026.
PharmEasy IPO Registrar Details
The registrar named in the earlier proposed IPO documents was Link Intime India Private Limited. The earlier DRHP provides the registrar’s Mumbai office and IPO contact details.
| Particular | Details |
|---|---|
| Registrar Name | Link Intime India Private Limited |
| Website | https://www.linkintime.co.in |
| IPO Allotment Status | Yet to be Updated |
| Email ID | [email protected] |
| Contact Number | +91 22 4918 6000 |
The registrar details above relate to the earlier proposed API Holdings IPO and should be reconfirmed if a new IPO is launched.
PharmEasy IPO Lead Manager Details
The Book Running Lead Managers named in the earlier API Holdings IPO documents were responsible for managing the proposed issue.
| Particular | Details |
|---|---|
| Lead Managers | Kotak Mahindra Capital Company Limited, Morgan Stanley India Company Private Limited, BofA Securities India Limited, Citigroup Global Markets India Private Limited and JM Financial Limited |
The five institutions were identified as the Book Running Lead Managers in the earlier DRHP.
API Holdings Limited Contact Details
| Particular | Details |
|---|---|
| Company Name | API Holdings Limited |
| Registered Office | 4th Floor, Plot No. D-37/3, TTC MIDC Industrial Area, Turbhe, Navi Mumbai – 400703, Maharashtra, India |
| Website | https://www.apiholdings.in |
| Email ID | [email protected] |
| Contact Person | Drashti S. Shah, Group General Counsel and Company Secretary |
The latest FY2025-26 annual report provides the registered office, website, telephone number and corporate secretarial email address of API Holdings Limited.
Prospectus / Documents
The following documents are relevant to the PharmEasy/API Holdings IPO:
| Document | Status |
|---|---|
| DRHP | Filed in November 2021 |
| RHP | Yet to be Updated |
| Prospectus | Yet to be Updated |
| Annual Report FY2025-26 | Available |
| Financial Statements FY2025-26 | Available |
The historical API Holdings DRHP was filed with SEBI in November 2021. The company’s latest FY2025-26 annual report and financial statements are available through the official API Holdings investor section.
How to Check PharmEasy IPO Allotment Status
Investors can check the PharmEasy IPO allotment status only after a future IPO is officially launched and the basis of allotment is finalised.
Through Registrar
- Visit the official IPO allotment portal of the appointed registrar.
- Select PharmEasy IPO or API Holdings IPO from the IPO list.
- Choose PAN Number, Application Number, or DP/Client ID.
- Enter the required details.
- Click Submit to view the allotment status.
Through BSE
- Visit the official BSE IPO allotment page.
- Select PharmEasy IPO from the list of IPOs.
- Enter your PAN Number or Application Number.
- Complete the verification process if required.
- Click Search to view the allotment result.
The current allotment status is not available because there is no active PharmEasy IPO issue.
PharmEasy IPO Conclusion
PharmEasy IPO refers to the proposed public offering of API Holdings Limited, the parent company of PharmEasy. API Holdings had filed a DRHP in 2021 proposing a fresh issue of up to ₹6,250 crore, with the proposed proceeds intended for debt repayment, organic growth, inorganic growth and general corporate purposes.
The company’s latest FY2025-26 financial statements show revenue from operations of ₹6,618.50 crore and a consolidated loss after tax of ₹520.29 crore. The company also reported improvement in EBITDA before exceptional items and ESOP expense and a reduction in borrowings during FY2026.
The current price band, issue dates, lot size, subscription figures, allotment date and listing date for a new PharmEasy IPO have not been officially announced. Therefore, these details should be updated only after API Holdings files the applicable fresh IPO documents.
PharmEasy IPO FAQs
What is PharmEasy IPO?
PharmEasy IPO refers to the proposed initial public offering of API Holdings Limited, the parent company of PharmEasy. API Holdings had earlier filed a DRHP for a proposed fresh issue of up to ₹6,250 crore.
What is the price band of PharmEasy IPO?
The price band of a new PharmEasy IPO has not yet been announced.
What is the issue size of PharmEasy IPO?
The earlier 2021 DRHP proposed a fresh issue of up to ₹6,250 crore. The issue size for any future IPO will depend on the new offer documents.
When will the PharmEasy IPO open?
The PharmEasy IPO opening date has not yet been officially announced.
When will the PharmEasy IPO close?
The PharmEasy IPO closing date has not yet been officially announced.
On which stock exchanges will PharmEasy shares be listed?
The earlier API Holdings IPO documents proposed listing on the BSE and NSE. A future listing structure will need to be confirmed in the applicable offer documents.
Who is the registrar for PharmEasy IPO?
Link Intime India Private Limited was named as the registrar to the earlier proposed API Holdings IPO. The registrar for any future issue will need to be confirmed in the new offer documents.
What is the face value of PharmEasy IPO shares?
The earlier API Holdings DRHP specified a face value of ₹1 per equity share.
What does API Holdings Limited do?
API Holdings operates an integrated healthcare business covering pharmaceutical distribution, PharmEasy’s digital healthcare marketplace, diagnostics, hospital supplies and technology-enabled healthcare services.
What are the objects of the PharmEasy IPO?
Under the earlier proposed IPO, the company intended to use the fresh issue proceeds for repayment or prepayment of borrowings, organic growth initiatives, acquisitions and strategic initiatives, and general corporate purposes.
